Global Non-small Cell Lung Cancer Consumption Market Expected to Reach US$ 15.1 Bn in 2023

Albany, New York, December 9, 2016: A recent forecast report has been added to the vast archive of report offerings belonging to Market Research Hub (MRH). This research study is titled as “Global Drugs for Non-small Cell Lung Cancer Market Research Report 2016”, and has been prepared using in-depth market analysis with inputs from industry experts. It also covers the market landscape and growth prospects in the coming years.

Request for Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=895861

This report studies Drugs for Non-small Cell Lung Cancer in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer like:-

• Bristol-Myers Squibb
• GlaxoSmithKline
• Menarini
• Sanofi
• ZIOPHARM Oncology
• Alchemia

The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to increase significantly over the forecast period across the leading eight developed nations, from $5.1 billion in 2013 to $7.9 billion in 2020. This equates to a Compound Annual Growth Rate (CAGR) of 6.6%. Growth will be driven by novel therapies entering the squamous cell carcinoma market segment, which is currently lacking effective treatment, unlike the non-squamous market segment.

Browse Full Info with TOC: http://www.marketresearchhub.com/report/global-drugs-for-nonsmall-cell-lung-cancer-market-research-report-2016-report.html

The report focuses on the increasing differentiation between the three main NSCLC subtypes: squamous cell, adenocarcinoma, and large cell carcinoma. Common genetic and molecular aberrations within these histologies are being extensively researched and targeted by novel therapeutics and so the treatment algorithm between histological subtypes is forecast to become more differentiated over the forecast period. Most notably, patients with squamous cell carcinoma are set to benefit from crucial first- and second-line therapies in the form of Yervoy (ipilimumab) and nivolumab, having relied on generic chemotherapy for the past decade. Non-squamous patients, on the other hand, have several successful histology-specific therapies, such as Alimta (pemetrexed), and mutation-specific therapies, such as Tarceva (erlotinib), that are already marketed.

Global non-small-cell lung cancer market is segmented into types, therapeutics and geography. Based on the types, global non-small-cell lung cancer market is further segmented into squamous cell carcinoma, adenocarcinoma, large cell carcinoma and others. The market is segmented on the basis of therapeutics into chemotherapy, targeted therapy, surgery, radiotherapy and pipeline drugs. Furthermore, the market is segmented, on the basis of geography, across North America, Europe, Asia-Pacific and LAMEA. Key players profiled in the market are Pfizer, Roche, AstraZeneca, Eli Lily, GlaxoSmithKline, Novartis AG, Merck & Co., and Agennix AG. Collaboration, product launch and acquisition are some of the strategies adopted by key players in the non-small cell lung cancer market.

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

90 State Street,
Albany, NY 12207,
United States
Toll Free : 866-997-4948 (US-Canada)
Tel : +1-518-621-2074
Email : press@marketresearchhub.com
Website : http://www.marketresearchhub.com/

This release was published on openPR.